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Background: Complementary and alternative medicine is often used by patients with malignant glioma. Although
several interactions of various alternative agents with chemotherapy are known, none has been described for
temozolomide so far.
Case presentation: We report the case of severe liver toxicity with jaundice during radiochemotherapy with
temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma.
After cessation of the herbal formula as well as the chemotherapy liver enzymes slowly normalized. Due to
tumor progression the patient was retreated with temozolomide for 5 cycles without toxicity. Because of further
progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was
observed.
Conclusions: We conclude that the observed toxicity with jaundice was probably caused by an interaction of
this popular Chinese formula and temozolomide. This is the first report about a relevant interaction of
temozolomide and any herbal formula.
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Complementary and alternative medicine (CAM) is fre-
quently used by glioblastoma patients [1] but treating
physicians are often left uninformed about its use. These
patients are potentially at increased risk for herb-drug
interactions resulting in increased toxicity due to higher
serum levels of cytostatics on the one hand or under-
treatment due to decreased efficacy caused by lower
serum levels on the other hand.Case presentation
A 56 year old female Caucasian patient was diagnosed with
a temporal-parietal glioblastoma WHO IV° after further
evaluation for cephalea. Complete resection was performed
using 5-aminolevulinic acid guided surgery and postopera-
tive magnetic resonance investigation showed a small rest
tumor. The patient had a Karnofsky performance status* Correspondence: a.egle@salk.at
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unless otherwise stated.scale of 90% after resection without neurological defi-
ciencies and was referred to our department for further
treatment with radiotherapy and temozolomide (TEM).
Co-medication consisted of dexamethason 4 mg per
day because of edema, pantoprazol, levetiracetam and
mirtazapine because of depression. Further medical his-
tory consisted of hypertension and recurrent cutaneous
herpes infections. Adjuvant concomitant radiochemother-
apy (RCT) was started with an absolute dose of 140 mg
TEM per day 4 weeks after primary resection. Further-
more, prophylactic valaciclovir was prescribed. Treatment
was initially well tolerated and the steroid was tampered.
Unfortunately, TEM had to be stopped after 32 days of
treatment and 24 fractions of radiotherapy because of
grade II° thrombopenia and increasing liver enzymes. Mir-
tazapine, valaciclovir and pantoprazol were paused and
radiotherapy was completed as planned after 30 fractions.
Because of further increasing liver enzymes and jaundice
(bilirubin: 16.7 mg/dl; AST: 263 U/l; ALT: 585 U/l) the pa-
tient was hospitalized and underwent further evaluation
including exclusion of viral hepatitis, Epstein-Barr virus or
cytomegalovirus-infection, computed tomography scan asral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Course of liver enzymes during primary radiochemotherapy with temozolomide and re-exposition for 5 cycles after first
diagnosis of glioblastoma.
Table 1 Modified form of the Chinese herbal formula
called Bu Zhong Yi Qi Wan
Chinese name Name and species
Dang Shen Radix Codonopsitis
Zhi Gan Cao Radix Glycyrrhizae
Bai Zhun Rhizoma Atractylodes macrocephala
Huang Qi Radix Astragali
Chen Pi Citrus reticulata
Chai Hu Radix Bupleuri
Sheng Ma Rhizoma Cimicifugae
Dang Gui Radix Angelicae sinensis
Ge Gen Radix Puerariae
Du Zhong Cortex eucommiae
Huang Qin Radix Scutellariae
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hepatitis. Endoscopic retrograde endoscopy excluded path-
ology of the biliary or pancreatic ductal system. A negative
herpes polymerase chain reaction ruled out systemic her-
pes infection and levetiracetam was reduced in the absence
of seizures with the intention to reduce co-medications.
After repeated and detailed conversations the patient
reported the use of Chinese herbs as a decoction twice
daily for 2 weeks between the beginning of the RCT and
the diagnosis of increasing liver enzymes. Following the
diagnosis of glioblastoma a general practitioner special-
ized in CAM recommended the use of a modified form
of the Chinese herbal formula called Bu Zhong Yi Qi
Wan (11 different herbs) compiled by a local pharmacy,
which is commonly used in Chinese CAM. Four weeks
after cessation of TEM and the Chinese herbs the liver
enzymes started to decrease, but it took about 3 months
to normalization of the bilirubin level (Figure 1).
Unfortunately, a [18 F]-fluorethylenthyrosin positron
emission tomography positive residual tumor was detec-
ted 2 months after the end of radiotherapy. Therefore,
despite normalization of the liver parameters was still
pending we decided to restart TEM after repeated briefing
of the patient to omit any CAM, because we were con-
vinced that this toxic hepatitis was primarily caused by the
addition of this Chinese herbal formula. Thus, TEM with
an absolute dose of 250 mg per day for 5 days every
4 weeks was re-introduced, supportive medication with
valaciclovir and 500 mg bi-daily levetiracetam remainedunchanged. We continued treatment for 5 cycles of TEM
without any increase of the liver parameters or any other
toxicity except for mild cytopenia. Thereafter the patient
did not want to continue treatment despite response, be-
cause she desired to undergo further complementary
treatment. Unfortunately, 3 months after cessation of
therapy symptomatic progression due to large edema
was diagnosed and combination treatment of bevaci-
zumab and irinotecan was initiated. No liver toxicity
or any other severe side effect was observed after
3 months of treatment.
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Liver toxicity is a known but very rare side effect of TEM
[2]. Reexpositions to TEM in our patient showed that
toxic hepatitis was not causally related to TEM treatment
alone or caused by the combination with valaciclovir or
levetiracetam. Thus, we conclude that the observed liver
toxicity was caused by the concomitant intake of the
popular Chinese herbal formula, Bu Zhong Yi Qi Wan, in
combination with TEM. Some direct hepatotoxicity by the
herbal formula itself seems unlikely, because in traditional
Chinese medicine Bu Zhong Yi Qi Wan is thought to be
protective to the liver, but cannot be completely ruled out.
To exclude an unknown toxic product in the formula we
asked for some remnants of this formula, but unfortu-
nately it was totally used up by the patient. Furthermore,
the Chinese herbs were recommended by a physician not
involved in the management of the patient and probable
not familiar with GBM. Due to that we were primarily not
aware of this possible interaction and this delayed clarifi-
cation of this case.
This herbal formula consists of several different herbs
and the exact composition varies frequently in CAM.
The detailed list of herbs taken by our patient is shown
in Table 1 and comprises at least two herbs Huang Qi
and Huang Qin with relevant cytochrome P450 3A4
(CYP3A4) inhibition [3,4]. The effect and safety of temo-
zolomide was not addressed in patients with severe hep-
atic impairment in clinical trials, but no dose adjustment
is recommended in these patients according to manufac-
turer’s labeling. TEM is nonenzymatically converted to
the active alkylating metabolite in all tissues and ex-
creted with the urine, therefore CYP isoenzymes are
thought to play a minor role up to now. Nevertheless,
the distribution of single nucleotide polymorphisms of
the CYP450 system is different in Chinese compared to
other populations [5]. This would in part explain, why
such an interaction is observed in Europe but not in
China so far despite integration of TEM in the national
insurance schedule in China [6]. Furthermore, Chinese
medicine comprises hundreds if not thousands of prepa-
rations. It may well slip the attention of physicians if a
broad background of intake is assumed.
Furthermore, liver toxicity due to pantoprazol or
mirtazapine seems unlikely, because they were started
6 weeks before the start of RCTX without any tox-
icity and the overall low incidence of liver toxicity of
these drugs.
Nevertheless, while the exact mechanism remains un-
clear, we still observed a severe liver toxicity with the
combination of TEM and a popular Chinese formula,
which is not reported up to now in the literature. In face
of the frequent use of CAM and Chinese herbs in pa-
tients with malignant glioma we want to alert cancer
physicians about this possible side effect.We hope to inspire the discussion about the safety of
any herbal formulas in combination with cytotoxic therap-
ies and encourage physicians to seek faithful conversations
dealing with the use of CAM in cancer patients. There are
several reports on the detrimental effects of CAM on the
efficacy of chemotherapeutic agents such as St. John’s wort
with irinotecan or imatinib [7] or ascorbic acid and green
tea with bortezomib [8,9] to name but a few. Therefore,
we think that a comprehensive management of our
patients should also include education about the risk of
interactions with herbal formulas.
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